Finance

Beta
Lists
600812:SHA
North China Pharmaceutical Co Ltd
CNÂ¥4.43
+1.37%
(+0.060) 1D
Jun 5, 3:00:02 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600812...
Open
CNÂ¥4.36
High
CNÂ¥4.47
Low
CNÂ¥4.36
Avg. vol.
14.22M
Volume
12.13M
P/E ratio
47.20
52-wk high
CNÂ¥7.46
52-wk low
CNÂ¥4.35
EPS
CNÂ¥0.09
Shares outstanding
1.63B
No. of employees
10K
Open
CNÂ¥4.36
High
CNÂ¥4.47
Low
CNÂ¥4.36
Avg. vol.
14.22M
Volume
12.13M
P/E ratio
47.20
52-wk high
CNÂ¥7.46
52-wk low
CNÂ¥4.35
EPS
CNÂ¥0.09
Shares outstanding
1.63B
No. of employees
10K
News stories
From sources across the web
Profile
North China Pharmaceutical Group Corp., is a pharmaceutical manufacturer in China. NCPC was one of the key construction projects during China's First Five-Year Plan. After five years of construction since the foundation date in June 1953, the first successful pharmaceutical production, started in June 1958. Being one of the antibiotic producers both in technology and production scale at that time, NCPC created a history of commercial production of antibiotics in China. It has 45 years of development experience. NCPC has been taking the lead in the Chinese pharmaceutical industry in key economic indexes, ranked as one of the Top500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets of the company were valued at US$2 billion, with 18,500 employees. In 2002, NCPC claimed a domestic sales revenue of US$700 million and export sales of US$100 million. Wikipedia
About North China Pharmaceutical Co Ltd
CEO-
Employees9.97K
FoundedDec 20, 1992
Headquarters-
SectorPharmaceutical industry
Website-
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
2.70B
2.21B
1.76B
2.15B
Cost of goods sold
1.89B
1.59B
1.07B
1.53B
Cost of revenue
1.89B
1.59B
1.07B
1.53B
Research and development expenses
87.66M
85.19M
85.95M
95.62M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
489.41M
419.54M
414.91M
354.22M
Operating expense
624.85M
504.74M
539.54M
495.25M
Total operating expenses
2.51B
2.09B
1.61B
2.03B
Operating income
185.85M
116.01M
149.57M
128.11M
Other non operating income
-3.76M
-299.86K
-2.96M
-10.58M
EBT including unusual items
110.88M
73.18M
70.19M
66.28M
EBT excluding unusual items
117.76M
45.54M
84.31M
61.80M
Income tax expense
25.22M
23.93M
24.28M
16.90M
Effective tax rate
22.75%
32.70%
34.59%
25.50%
Other operating expenses
29.67M
4.82M
29.30M
27.82M
Net income
66.01M
35.01M
24.55M
35.47M
Net profit margin
2.44%
1.58%
1.40%
1.65%
Earnings per share
-
-
-
-
Interest and investment income
25.17M
19.41M
27.71M
19.26M
Interest expense
-93.24M
-85.85M
-85.06M
-74.99M
Net interest expenses
-68.08M
-66.43M
-57.35M
-55.73M
Depreciation and amortization charges
-
-
-
-
EBITDA
405.75M
313.14M
371.92M
350.45M
Gain or loss from assets sale
9.85K
-9.85K
-827.34K
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer